REED REED'S, INC. Insider Trading

Era Regenerative buys 1,075,269 REED shares, raising stake to 28.21M; stock down 45.2% from 52-week high.

Era Regenerative Medicine Ltd, a 10% owner, purchased 1,075,269 shares (1.08M shares) of REED'S, INC., increasing its post-transaction holdings to 28,214,789 shares (28.21M shares), a 4.0% increase from the 27,139,520 shares (27.14M shares) held pre-transaction. The purchase occurred as REED trades at $6.18, down 45.2% from its 52-week high of $11.28 and down 41.3% over the past 30 days, signaling a period of significant downward price pressure. The company's fundamentals remain challenged: revenue of $10,029,000.00 ($10.0M) in the latest quarter, net income of $-2,031,000.00 ($-2.0M), and annual revenue decline of 15.1%, indicating ongoing operational strain. A substantial insider accumulation during a sharp downturn, combined with persistent unprofitability and revenue contraction, warrants close examination of Era's investment rationale and whether this reflects a strategic repositioning or confidence that the decline has become excessive.

10% Owner Union Square Park Capital buys 531,205 shares of REED at $1.50, raising stake to 1,230,699 shares (+75.9%)

Union Square Park Capital Management acquired 531,205 shares at $1.50 on 2024-09-10, increasing its shareholding by 75.9% to 1,230,699 shares. At the current price of $7.98, the transaction now shows a gain of +432%, though the stock remains -61.8% from its 52-week high of $20.88 and down -21.8% over the past 90 days. The purchase occurred in a company with material operational headwinds: REED posted negative net income of $-3,212,000 in the latest quarter and annual revenue contracted -15.7% year-over-year. The insider's prior purchase at this ticker (2023-05-25) exhibited +1.4% 90-day return, demonstrating timing that captured subsequent recovery; the current transaction's significance depends on whether this markup from $1.50 to $7.98 reflects fundamental stabilization or valuation reset in an otherwise unprofitable, shrinking business.

Director DENG Shufen purchased 4,429,337 shares for $7,903,193.57 across two trades; enters position in loss-making company with declining revenue.

Director DENG acquired 4.43M shares in two separate transactions—1,160,542 shares at $2.58 on 2023-05-25 and 3,268,795 shares at $1.50 on 2024-09-10—for a blended average price of $1.78, building a new position of 4,429,337 shares. The timing of these purchases and their substantial size relative to the company's market cap ($31.2M) merit scrutiny, but the fundamental backdrop is critical: REED is unprofitable (net income of $-3.2M in the latest quarter, negative full-year net income) and experiencing revenue contraction (-15.7% annual decline). The second purchase on 2024-09-10 at $1.50 per share occurred while the stock was trading at -64.4% from its 52-week high of $20.88, and the subsequent 30-day and 90-day declines (-18.4% and -24.8% respectively) indicate continued deterioration. These purchases by a director of a substantially impaired company warrant close examination of the insider's rationale and any knowledge of material developments not yet reflected in public filings.